# Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

> **NCT00639626** · PHASE2,PHASE3 · TERMINATED · sponsor: **Nationwide Children's Hospital** · enrollment: 6 (actual)

## Conditions studied

- Cystic Fibrosis Related Diabetes

## Interventions

- **DRUG:** insulin detemir [rDNA origin] injection

## Key facts

- **NCT ID:** NCT00639626
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** PI left the institution
- **Last updated:** 2018-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639626, "Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00639626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*